What is the 13F Pro Quality Score for MAZE?

13F Pro ranks Maze Therapeutics, Inc. (MAZE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MAZE's current score at https://13fpro.ai/research/MAZE (free sign-up required for the full ranking).

Where does 13F Pro source MAZE data?

All Maze Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Maze Therapeutics, Inc. files with the SEC under CIK 1842295. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MAZE in?

Maze Therapeutics, Inc. (MAZE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MAZE research updated on 13F Pro?

MAZE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Maze Therapeutics, Inc.(MAZE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1842295 MAZE stock profile & AI dashboard →

13F Pro Quality Score

19.7/100

Rank #2,687 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

3.1/100

Profitability

30.0/100

Balance Sheet

7.4/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

12.0/100

Revenue Scale

30.0/100

Dilution Risk

17.0/100

MAZE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Maze Therapeutics, Inc. (MAZE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MAZE at 19.7/100 on a 32-signal composite quality model, placing it at rank #2,687 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (3.1) and balance sheet strength (7.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Maze Therapeutics, Inc. reports quarterly revenue of $20.0M, net income of $-24.2M, free cash flow of $-39.2M. Top institutional holders of MAZE by reported 13-F value include Frazier Life Sciences Management, L.P., TRV GP IV,, ARCH Venture Management,, based on the most recent SEC filings. MAZE trades on the Nasdaq exchange and files with the SEC under CIK 1842295. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MAZE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Maze Therapeutics, Inc. directly from SEC EDGAR.

✦

Fun facts about Maze Therapeutics, Inc.

Quirks, history, and lore behind MAZE — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in South San Francisco, the biotech capital of the world.
2
The Numbers
Like most clinical-stage biotechs, it generates minimal product revenue and burns cash on R&D — its pipeline, not its income statement, is the whole investment thesis.
3
The History
Founded in 2019 by veterans of Genentech and the Broad Institute, it was built from the ground up around a single big scientific bet on human genetics.
4
The Secret
Its platform mines human genetic variants — natural mutations in real people — to identify which biological targets are actually worth drugging, filtering out the ones likely to fail in trials.
5
The Lore
The company's Human Genetics Engine is its crown jewel, designed to do what most pharma R&D notoriously cannot: pick winners before the clinic, not after.
6
The Giveaway
Its name evokes navigating a complex labyrinth of genetic data — and its ticker symbol is exactly the word you'd shout if you got lost in one: MAZE.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$20.0M

Net Income

Q1 2026

$-24.2M

Free Cash Flow

Q1 2026

$-39.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY23 —FY24 $167.5MFY25 —

Net Income

-351.0% YoY

$-131.1MFY 2025

FY23 —FY24 $52.2MFY25 $-131.1M

Operating Income

-348.1% YoY

$-142.9MFY 2025

FY23 —FY24 $57.6MFY25 $-142.9M

EPS (Diluted)

-4494.8% YoY

$-3.05FY 2025

FY23 —FY24 $0.07FY25 $-3.05

Total Assets

+65.1% YoY

$397.1MFY 2025

FY23 —FY24 $240.5MFY25 $397.1M

Op. Cash Flow

-247.4% YoY

$-111.9MFY 2025

FY23 —FY24 $76.0MFY25 $-111.9M

Metric	FY 2025	FY 2024	FY 2023
Revenue	—	$167.5M	—
Net Income	$-131.1M -351.0%	$52.2M	—
Operating Income	$-142.9M -348.1%	$57.6M	—
EPS (Diluted)	$-3.05 -4494.8%	$0.07	—
Total Assets	$397.1M +65.1%	$240.5M	—
Operating Cash Flow	$-111.9M -247.4%	$76.0M	—

AI Insight: MAZE Financial Trends

Maze swung to positive revenue in Q1 2026 but operating losses persist; cash burn accelerated despite top-line emergence.

• Revenue appeared in Q3 2025 ($168M) and Q1 2026 ($20M); Q4 2025 showed $0M, suggesting volatile or lumpy recognition.

• Operating losses remained consistent: Q1–Q2 2025 averaged $-36M; Q1 2026 at $-27M shows modest improvement but still deeply negative.

• Operating cash flow deteriorated to $-39M in Q1 2026, worst quarter in the dataset, despite revenue appearance.

⚠ Debt appeared for first time in Q1 2026 at $39M; equity declined from $379M (Q3 2025 peak) to $342M—leverage rising.

⚠ Revenue quality uncertain: $168M in Q3 2025 followed by $0M in Q4, then $20M in Q1 2026 lacks visibility.

AI Insight: MAZE Ratio Trends

Maze swung to massive operating losses in Q1 2026, with OpMargin plummeting to -132.8%, though return metrics stabilized versus prior quarters.

• OpMargin deteriorated sharply to -132.8% in Q1 2026 from -19.7% in Q3 2025, signaling a material quarterly loss spike.

• ROE improved to -28.3% in Q1 2026 from -51.4% in Q2 2025, indicating sequential recovery in return metrics.

• Debt-to-equity stable at 0.11 in both TTM and Q1 2026, suggesting leverage remains controlled despite operational pressure.

⚠ Q1 2026 OpMargin of -132.8% is extreme; confirm whether this reflects one-time charges or sustained operational deterioration.

⚠ Negative ROIC persists across all periods (-27.9% in Q1 2026); monitor for pathway to profitability and capital efficiency.

Get alerted when MAZE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Maze Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MAZE

Frazier Life Sciences Management, L.P.
$136.3M4,567,274 sh
TRV GP IV, LLC
$133.5M4,473,958 sh
ARCH Venture Management, LLC
$123.0M4,120,053 sh
Deep Track Capital, LP
$103.8M3,477,562 sh
JANUS HENDERSON GROUP PLC
$85.3M2,858,876 sh
Paradigm Biocapital Advisors LP
$81.9M2,744,399 sh
BlackRock, Inc.
$76.7M2,570,425 sh
a16z Capital Management, L.L.C.
$50.8M1,702,225 sh
VR Adviser, LLC
$47.8M1,602,034 sh
VANGUARD CAPITAL MANAGEMENT LLC
$42.9M1,435,656 sh

Fund	Value	Shares
Frazier Life Sciences Management, L.P.	$136.3M	4,567,274
TRV GP IV, LLC	$133.5M	4,473,958
ARCH Venture Management, LLC	$123.0M	4,120,053
Deep Track Capital, LP	$103.8M	3,477,562
JANUS HENDERSON GROUP PLC	$85.3M	2,858,876
Paradigm Biocapital Advisors LP	$81.9M	2,744,399
BlackRock, Inc.	$76.7M	2,570,425
a16z Capital Management, L.L.C.	$50.8M	1,702,225
VR Adviser, LLC	$47.8M	1,602,034
VANGUARD CAPITAL MANAGEMENT LLC	$42.9M	1,435,656

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MAZE on your watchlist

Track score changes the day Maze Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MAZE a good stock to buy?

13F Pro's AI-powered analysis of Maze Therapeutics, Inc. (MAZE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MAZE are available on the MAZE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MAZE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MAZE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Maze Therapeutics, Inc.'s investment landscape.